Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab

Cutis

Volumn 76, Issue 2, 2005, Pages 129-132

  Vujevich, Justin ^a   Zirwas, Matthew ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Oakland Medical Bldg   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; APHTHOUS STOMATITIS; ARTICLE; CASE REPORT; HUMAN; IMMUNOLOGY; MALE; RECURRENT DISEASE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; HUMANS; MALE; RECURRENCE; STOMATITIS, APHTHOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 24744438466     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Stanley HR. Aphthous lesions. Oral Surg Oral Med Oral Pathol Oral. 1972;33:407-416.
2. Miller MF, Garfunkel AA, Ram CA, et al. The inheritance of recurrent aphthous stomatitis, observations on susceptibility. Oral Surg Oral Med Oral Pathol. 1980;49:409-412.
3. Wray D, Graykowski EA, Norkins AL. Role of mucosal injury in initiating recurrent aphthous stomatitis. Br Med J (Clin Res Ed). 1981;283:1569-1570.
4. Ship II, Morris AL, Durocher RT, et al. Recurrent ulcerations and recurrent herpes labialis in a professional school student population. Oral Surg Oral Med Oral Pathol. 1960;13:1191-1202.
5. Eglin RP, Lehner T, Subak-Sharpe JH. Detection of DNA complementary to herpes-simplex virus in mononuclear cells from patients with Behçet's syndrome and recurrent oral ulcers. Lancet. 1982;18:1356-1361.
6. Thomas HC, Ferguson A, McLennan JG, et al. Food antibodies in oral disease: a study of serum antibodies to food proteins in aphthous ulceration and other oral diseases. J Clin Pathol. 1973;26:371-374.
7. Porter SR, Scully C. Orofacial manifestations in primary immunodeficiencies involving IgA deficiency. J Oral Pathol Med. 1993;22:117-119.
8. Scully C, Gorsky M, Lozada-Nur F. Aphthous ulcerations. Dermatol Ther. 2002;15:185-205.
9. Borra RC, Andrade PM, Silva ID, et al. The Th1/Th2 immune-type response of the recurrent aphthous ulceration analyzed by cDNA microarray. J Oral Pathol Med. 2004;33:140-146.
10. Buno IJ, Huff JC, Weston WL, et al. Elevated levels of interferon gamma, tumor necrosis factor alpha, interleukins 2, 4, and 5, but not interleukin 10, are present in recurrent aphthous stomatitis. Arch Dermatol. 1998;134:827-831.
11. Natah SS, Hayrinen-Immonen R, Hietanen J, et al. Immunolocalization of tumor necrosis factor-alpha expressing cells in recurrent aphthous ulcer lesions (RAU). J Oral Pathol Med. 2000;29:19-25.
12. Taylor LJ, Bagg J, Walker DM, et al. Increased production of tumour necrosis factor by peripheral blood leukocytes in patients with recurrent oral aphthous ulceration. J Oral Pathol Med. 1992;21:21-25.
13. Robinson ND, Guitart J. Recalcitrant, recurrent aphthous stomatitis treated with etanercept. Arch Dermatol. 2003;139:1259-1262.
14. Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. Biodrugs. 2004;18:121-139.
15. Wahba-Yahav AV. Pentoxifylline in intractable recurrent aphthous stomatitis: an open trial. J Am Acad Dermatol. 1995;33:680-682.
16. Revuz J, Guillaume JG, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol. 1990;126:923-927.
17. Kaufman I, Caspi D, Yeshurun D, et al. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int. August 12, 2004; [Epub ahead of print]. Available at: http://www.springerlink.com/app/home/ contribution.asp?wasp=439297a7d65044d9b5fdf6561240c0a2&referrer= parent&backto=issue,89,108,journal,1,52;linkingpublicationresults,1:101577, 1. Accessed February 10, 2005.
18. Khanna D, McMahon M, Furst D. Safety of tumour necrosis factor-alpha antagonists. Drug Saf. 2004;27:304-324.